Citations

Clear

4847 citation(s) found for "Yu, Eric".

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
Xu‐Monette, Zijun Y. , Zhang, Hongwei , Zhang, Hongwei, Zhu, Feng, Tzankov, A, Bhagat, Govind , Visco, Carlo , Dybkær, Karen , Chiu, April , Tam, Wayne , Zu, Youli , You, Hua , Huh, Jooryung, Ponzoni, Maurilio, Ferreri, Andrés J.M. , Møller, Michael , Parsons, Benjamin M. , Krieken, J. Han van, Piris, Miguel A., Winter, Jane N., Hagemeister, Fredrick B., Shahbaba, Babak , Dios, Ivan De , Zhang, Hong, Zhang, Hong, Li, Yong, Xu, Bing, Albitar, Maher , Young, Ken H. , Tzankov, Alexandar , Li, Yong , Møller, Michael Boe , Tzankov, Alexandar , Dybkaer, Karen , Parsons, Benjamin M , Young, Ken H , Li, Yong , Bhagat, Govind , Zu, Youli , Xu-Monette, Zijun Y , Chiu, April , Hsi, Eric D. , Ponzoni, Maurilio , Winter, J N

Mayo Clinic

Blood Advances | July 28, 2020 | Volume: 4 | Issue: 14 | Pages: 3391-3404

10.1182/bloodadvances.2020001949 | PMID 32722783 Get It

Abstract Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous entity of B-cell lymphoma. Cell-of-origin (COO) classification of DLBCL is required in routine practice by the World Health Organization classification for biological and therapeutic insights. Genetic subtypes uncovered recently are based on distinct genetic alterations in DLBCL, which are different from the COO subtypes defined by gene expression signatures of normal B cells retained in DLBCL. We hypothesize that classifiers incorporating both genome-wide gene-expression and pathogenetic variables can improve the therapeutic significance of DLBCL classification. To develop such refined classifiers, we performed targeted RNA sequencing (RNA-Seq) with a commercially available next-generation sequencing (NGS) platform in a large cohort of 418 DLBCLs. Genetic and transcriptional data obtained by RNA-Seq in a single run were explored by state-of-the-art artificial intelligence (AI) to develop a NGS-COO classifier for COO assignment and NGS survival models for clinical outcome prediction. The NGS-COO model built through applying AI in the training set was robust, showing high concordance with COO classification by either Affymetrix GeneChip microarray or the NanoString Lymph2Cx assay in 2 validation sets. Although the NGS-COO model was not trained for clinical outcome, the activated B-cell–like compared with the germinal-center B-cell–like subtype had significantly poorer survival. The NGS survival models stratified 30% high-risk patients in the validation set with poor survival as in the training set. These results demonstrate that targeted RNA-Seq coupled with AI deep learning techniques provides reproducible, efficient, and affordable assays for clinical application. The clinical grade assays and NGS models integrating both genetic and transcriptional factors developed in this study may eventually support precision medicine in DLBCL.
Colorectal surgery training and the COVID pandemic
Kelley, Scott R. , Mathis, Kellie L. , Dozois, Eric J. , Kelley, Scott R

Mayo Clinic

The Clinical Teacher | July 28, 2020 | Volume: 17 | Issue: 4 | Pages: 413-414

10.1111/tct.13202 | PMID 33189092 Get It

Ethics and informatics in the age of COVID-19: challenges and recommendations for public health organization and public policy
Subbian, Vignesh , Clarkson, Melissa D. , Rahimzadeh, Vasiliki , Petersen, Carolyn , Schreiber, Richard , DeMuro, Paul R. , Dua, Prerna, Goodman, Kenneth W. , Kaplan, Bonnie J. , Lehmann, Christoph U. , Pan, Eric, Goodman, Kenneth W , Lehmann, Christoph U , Petersen, Carolyn , Subbian, Vignesh , Solomonides, Anthony , Kaplan, Bonnie, Koppel, Ross , Senathirajah, Yalini

Mayo Clinic

Journal of the American Medical Informatics Association | July 24, 2020 | Volume: 28 | Issue: 1 | Pages: 184-189

10.1093/jamia/ocaa188 | PMID 32722749 Get It

AbstractThe COVID-19 pandemic response in the United States has exposed significant gaps in information systems and processes that prevent timely clinical and public health decision-making. Specifically, the use of informatics to mitigate the spread of SARS-CoV-2, support COVID-19 care delivery, and accelerate knowledge discovery bring to the forefront issues of privacy, surveillance, limits of state powers, and interoperability between public health and clinical information systems. Using a consensus-building process, we critically analyze informatics-related ethical issues in light of the pandemic across 3 themes: (1) public health reporting and data sharing, (2) contact tracing and tracking, and (3) clinical scoring tools for critical care. We provide context and rationale for ethical considerations and recommendations that are actionable during the pandemic and conclude with recommendations calling for longer-term, broader change (beyond the pandemic) for public health organization and policy reform.
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer
Eastham, James A., Halabi, Susan , Monk, J. Paul, Beltran, Himisha , Evans, Christopher P. , Clinton, Steven K. , Watt, Colleen, Sanda, Martin G. , Hahn, Olwen, Taplin, Mary-Ellen, Parsons, J. Kellogg , Mohler, James L. , Hillman, David W. , Halabi, Susan , Heller, Glenn , Gleave, Martin , Szmulewitz, Russell Z , Coleman, Jonathan , George, Saby , Taplin, Mary‐Ellen , Small, Eric J. , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | July 24, 2020 | Volume: 38 | Issue: 26 | Pages: 3042-3050

10.1200/jco.20.00315 | PMID 32706639 Get It

PURPOSE Radical prostatectomy (RP) alone is often inadequate in curing men with clinically localized, high-risk prostate cancer (PC). We hypothesized that chemohormonal therapy (CHT) with androgen-deprivation therapy plus docetaxel before RP would improve biochemical progression–free survival (BPFS) over RP alone. PATIENTS AND METHODS Men with clinically localized, high-risk PC were assigned to RP alone or neoadjuvant CHT with androgen deprivation plus docetaxel (75 mg/m 2 body surface area every 3 weeks for 6 cycles) and RP. The primary end point was 3-year BPFS. Biochemical failure was defined as a serum prostate-specific antigen level > 0.2 ng/mL that increased on 2 consecutive occasions that were at least 3 months apart. Secondary end points included 5-year BPFS, overall BPFS, local recurrence, metastasis-free survival (MFS), PC-specific mortality, and overall survival (OS). RESULTS In total, 788 men were randomly assigned. Median follow-up time was 6.1 years. The overall rates of grade 3 and 4 adverse events during chemotherapy were 26% and 19%, respectively. No difference was seen in 3-year BPFS between neoadjuvant CHT plus RP and RP alone (0.89 v 0.84, respectively; 95% CI for the difference, −0.01 to 0.11; P = .11). Neoadjuvant CHT was associated with improved overall BPFS (hazard ratio [HR], 0.69; 95% CI, 0.48 to 0.99), improved MFS (HR, 0.70; 95% CI, 0.51 to 0.95), and improved OS (HR, 0.61; 95% CI, 0.40 to 0.94) compared with RP alone. CONCLUSION The primary study end point, 3-year BPFS, was not met. Although some improvement was seen in secondary end points, any potential benefit must be weighed against toxicity. Our data do not support the routine use of neoadjuvant CHT and RP in patients with clinically localized, high-risk PC at this time.
National trends in prescription drug expenditures and projections for 2020
Tichy, Eric M. , Schumock, Glen T., Hoffman, James M. , Suda, Katie J. , Rim, Matthew H, Tadrous, Mina , Stubbings, JoAnn , Cuéllar, Sandra , Clark, John Spencer , Wiest, Michelle D., Matusiak, Linda M., Hunkler, Robert J., Vermeulen, Lee C.

Mayo Clinic

American Journal of Health-System Pharmacy | July 23, 2020 | Volume: 77 | Issue: 15 | Pages: 1213-1230

10.1093/ajhp/zxaa116 | PMID 32412055 Get It

Abstract Purpose To report historical patterns of pharmaceutical expenditures, to identify factors that may influence future spending, and to predict growth in drug spending in 2020 in the United States, with a focus on the nonfederal hospital and clinic sectors. Methods Historical patterns were assessed by examining data on drug purchases from manufacturers using the IQVIA National Sales Perspectives database. Factors that may influence drug spending in hospitals and clinics in 2020 were reviewed, including new drug approvals, patent expirations, and potential new policies or legislation. Focused analyses were conducted for specialty drugs, biosimilars, and diabetes medications. For nonfederal hospitals, clinics, and overall (all sectors), estimates of growth of pharmaceutical expenditures in 2020 were based on a combination of quantitative analyses and expert opinion. Results In 2019, overall US pharmaceutical expenditures grew 5.4% compared to 2018, for a total of $507.9 billion. This increase was driven to similar degrees by prices, utilization, and new drugs. Adalimumab was the top drug in US expenditures in 2019, followed by apixaban and insulin glargine. Drug expenditures were $36.9 billion (a 1.5% increase from 2018) and $90.3 billion (an 11.8% increase from 2018) in nonfederal hospitals and clinics, respectively. In clinics, growth was driven by new products and increased utilization, whereas in hospitals growth was driven by new products and price increases. Several new drugs that will likely influence spending are expected to be approved in 2020. Specialty and cancer drugs will continue to drive expenditures. Conclusion For 2020 we expect overall prescription drug spending to rise by 4.0% to 6.0%, whereas in clinics and hospitals we anticipate increases of 9.0% to 11.0% and 2.0% to 4.0%, respectively, compared to 2019. These national estimates of future pharmaceutical expenditure growth may not be representative of any particular health system because of the myriad of local factors that influence actual spending.
Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy
Nair, Dileep , Laxer, Kenneth D. , Weber, Peter, Murro, Anthony M., Park, Yong D., Barkley, Gregory L., Smith, Brien, Gwinn, Ryder P. , Doherty, Michael J. , Zimmerman, Richard S. , Bergey, Gregory K. , Anderson, William S. , Heck, Christianne, Liu, Charles Y. , Lee, Ricky W. , Sadler, Toni, Duckrow, Robert B., Wharen, Robert E. , Tatum, William O. , Srinivasan, Shraddha, Agostini, Mark, Alexopoulos, Andreas V. , Jobst, Barbara C. , Roberts, David W. , Salanova, Vicenta , Witt, Thomas C., Cash, Sydney S. , Halford, Jonathan J. , Spencer, David , Ernst, Lia , Skidmore, Christopher , Sperling, Michael R. , Miller, Ian , Geller, Eric B., Berg, Michel J., Fessler, A. James, Rutecki, Paul , Mizrahi, Eli M., Shields, Donald C. , Schwartz, Theodore H. , Labar, Douglas, Fountain, Nathan B. , Elias, W. Jeff, Olejniczak, Piotr W., Villemarette-Pittman, Nicole R. , Eisenschenk, Stephan, Roper, Steven N. , Boggs, Jane , Courtney, Tracy A., Sun, Felice T., Seale, Cairn G. , Miller, Kathy L. , Skarpaas, Tara L. , Morrell, Martha J. , Study, on behalf of the RNS System LTT, Meador, Kimford J. , Vossler, David G. , Hays, Ryan , Liow, Kore , Nair, Dileep R, Weber, Peter B, Smith, Brien J, Noe, Katherine H. , McKhann, Guy M. , Agostini, Mark A, Alexopoulos, Andreas V , Edwards, Jonathan C, Spencer, David C, Skidmore, Christopher T., Goldman, Alica M. , Gross, Robert E, Labar, Douglas R, Boggs, Jane G, Sperling, Michael R , Halford, Jonathan J , Fountain, Nathan , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J , Ernst, Lia D , Hirsch, Lawrence J. , Cole, Andrew J. , Worrell, Gregory A. , Lundstrom, Brian N. , Edwards, Jonathan C. W. , Gross, Robert E. , Study, on behalf of the RNS System LTT

Mayo Clinic

Neurology | July 20, 2020 | Volume: 95 | Issue: 9 | Pages: No page available

10.1212/wnl.0000000000010154 | PMID 32690786 Get It

Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders
Tichy, Eric M. , Prosser, Barbara, Doyle, Drew, Prosser, Barbara

Mayo Clinic

Journal of Pharmacy Practice | July 17, 2020 | Volume: 35 | Issue: 1 | Pages: 106-119

10.1177/0897190020938212 | PMID 32677504 Get It

Immunoglobulin G (IgG) is a commonly used treatment for chronic neuromuscular disorders (NMDs), such as chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. IgG therapy has also shown promise in treating other NMDs including myasthenia gravis, polymyositis, and dermatomyositis. IgG is administered as either intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg), with SCIg use becoming more popular due to the treatment burden associated with IVIg. IVIg requires regular venous access; long infusions (typically 4-6 hours); and can result in systemic adverse events (AEs) for some patients. In contrast, SCIg can be self-administered at home with shorter infusions (approximately 1 hour) and fewer systemic AEs. As patient care shifts toward home-based settings, the role of the pharmacist is paramount in providing a continuation of care and acting as the bridge between patient and clinic. Pharmacists with a good understanding of current recommendations, dosing strategies, and administration routes for IgG therapy are best placed to support patients. The aims of this review are to highlight the evidence supporting IgG therapy in the treatment of NMDs and provide practical information on patient management and IVIg/SCIg dosing in order to guide pharmacists on optimizing clinical outcomes and patient care.
Molecular genetic changes in solid pseudopapillary neoplasms (SPN) of the pancreas
Rodriguez-Matta, Elisa M., Hemmerich, Amanda, Starr, Jason S. , Mody, Kabir , Severson, Eric A. , Colón‐Otero, Gerardo , Rodriguez-Matta, Elisa, Starr, Jason, Colon-Otero, Gerardo

Mayo Clinic

Acta Oncologica | July 16, 2020 | Volume: 59 | Issue: 9 | Pages: 1024-1027

10.1080/0284186x.2020.1792549 | PMID 32672484 Get It

Cardiovascular outcomes of pregnancy in Turner syndrome
Grewal, Jasmine , Valente, Anne Marie , Egbe, Alexander C. , Wu, Fred , Sybert, Virginia P., Hagen, Iris M. van , Beauchesne, Luc , Rodriguez, Fred H. , Broberg, Craig S. , John, Anitha S. , Bradley, Elisa A. , Roos‐Hesselink, Jolien W. , van Hagen, Iris M , John, Anitha , Roos-Hesselink, Jolien W , Bradley, Elisa A , Krieger, Eric V.

Mayo Clinic

Heart | July 15, 2020 | Volume: 107 | Issue: 1 | Pages: 61-66

10.1136/heartjnl-2020-316719 | PMID 32669396 Get It

Objectives Women with Turner syndrome (TS) are frequently counselled against pregnancy due to lack of data and unclear aortic dissection risk. However, with advances in fertility therapy, more women with TS are contemplating pregnancy. This study compared rates of adverse cardiovascular (CV) outcomes among: (1) pregnant and non-pregnant women with TS and (2) pregnant women with TS with/without structural heart disease. Methods Retrospective analysis of pregnant and age-matched non-pregnant controls with TS (2005–2017) across 10 CV centres was done. Data were collected at initial evaluation in pregnancy and outcomes were assessed to 6 months postpartum. Adverse CV events were defined as CV death, aortic dissection/rupture and/or aortic intervention. Non-pregnant age-matched controls were followed over the same time period. Results Sixty-eight pregnancies were included (60 women, mean age 33 years, 48% primigravid, 49% fertility therapy, 80% structurally normal heart, 25% XO karyotype). Based on American Society of Reproductive Medicine criteria, 10 pregnancies occurred in women stratified to high-risk category. There were no CV events in the pregnant women or in the non-pregnant women with TS. Obstetric events complicated 12 (18%) pregnancies with 9 (13%) attributed to hypertensive disorder of pregnancy. Fetal events included small for gestational age neonates (18%), preterm delivery (15%) and fetal death (3%). Conclusions This study helps to refine the approach to pregnancy in women with TS. Among women with TS without structural heart disease, pregnancy does not impose an increased risk of CV outcomes. Among women with TS with structural heart disease, the risk of pregnancy is not as prohibitive as previously described but does require ongoing evaluation.